KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Abbott Laboratories (ABT) Gross Profit (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Gross Profit for 17 consecutive years, with $6.5 billion as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 8.37% to $6.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.0 billion through Dec 2025, up 7.59% year-over-year, with the annual reading at $25.0 billion for FY2025, 7.59% up from the prior year.
  • Gross Profit hit $6.5 billion in Q4 2025 for Abbott Laboratories, up from $6.3 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $6.9 billion in Q1 2022 to a low of $5.3 billion in Q2 2021.
  • Historically, Gross Profit has averaged $6.0 billion across 5 years, with a median of $5.9 billion in 2024.
  • Biggest five-year swings in Gross Profit: soared 36.22% in 2021 and later decreased 21.6% in 2023.
  • Year by year, Gross Profit stood at $6.7 billion in 2021, then decreased by 17.96% to $5.5 billion in 2022, then rose by 3.4% to $5.7 billion in 2023, then grew by 6.1% to $6.0 billion in 2024, then increased by 8.37% to $6.5 billion in 2025.
  • Business Quant data shows Gross Profit for ABT at $6.5 billion in Q4 2025, $6.3 billion in Q3 2025, and $6.3 billion in Q2 2025.